Assessing How Normal Variations in CT Scanning Affects Its Interpretation
| Status: | Recruiting |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/11/2018 |
| Start Date: | January 27, 2017 |
| End Date: | January 27, 2019 |
| Contact: | Kinh Gian Richard Do, MD, PhD |
| Email: | dok@mskcc.org |
| Phone: | 212-639-8591 |
Stability of Radiomic Features for Abdominal Tumors on Contrast Enhanced CT
The purpose of the study is to see how measurements of tumor differences vary with slight
changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal
tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even
in the setting of variable scan parameters and variable contrast timing. Participants will be
consented to undergo an additional CT of their abdomen.
changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal
tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even
in the setting of variable scan parameters and variable contrast timing. Participants will be
consented to undergo an additional CT of their abdomen.
Inclusion Criteria:
- Patients ≥ 18 years of age on the day of signed informed consent
- Patients scheduled and approved for contrast enhanced CT that includes imaging of the
abdomen and pelvis following the Department of Radiology standard of care protocol
- Patients with measurable colorectal liver metastases on prior imaging, with at least
one tumor greater than 2.0 cm in axial maximal diameter
Exclusion Criteria:
- Patient who is pregnant and/or lactating
- Patient scheduled for CT that includes the abdomen with a multiphasic contrast
enhanced protocol (e.g. Triple Phase or Quadruple Phase Liver CT)
- Patient who require reduced intravenous contrast dose based on the Department of
Radiology contrast policy
- Any other medical condition, including mental illness or substance abuse, deemed by
the Investigator to be likely to interfere with a patient's ability to sign informed
consent, cooperate and participate in the study, or follow up procedures
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Kinh Gian Richard Do, MD, PhD
Phone: 212-639-8591
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
